# Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

> **NCT02704767** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Kunming Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Tarceva
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02704767
- **Lead sponsor:** First Affiliated Hospital of Kunming Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02704767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02704767, "Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02704767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*